{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:59:44Z","timestamp":1793145584490,"version":"4.5.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Cellular therapies, particularly chimeric antigen receptor (CAR)-modified lymphocytes, have progressed from experimental oncology into serious consideration for selected autoimmune rheumatic diseases. Autologous and emerging allogeneic CAR-T platforms now offer the possibility of deep, drug-free remission in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), and related conditions for which conventional therapies remain inadequate. This timely article reviews the rationale, current clinical experience, safety profile, and future directions of cell therapies in rheumatology with a focus on efficacy, safety, and \u201cimmune reset\u201d in autoimmune rheumatic disease. The review is particularly pertinent as multiple parallel cell-based platforms (autologous and allogeneic CAR T cells, transient RNA CARs, CAR-NK, and T cell engagers) are entering the rheumatology space faster than practice guidelines or trial frameworks can fully adjust.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Recent studies show that CD19-directed CAR T cells can induce deep B-cell depletion with high rates of drug-free remission in refractory SLE and promising responses in SSc and IIM, accompanied by distinctive toxicity patterns such as mostly low-grade CRS, rare ICANS, and the newly described organ-specific LICATS. Parallel work demonstrates mechanistic \u201cimmune reset\u201d (including type I IFN pathway suppression and na\u00efve-skewed B-cell repopulation), expansion of indications to neurologic autoimmunity, emergence of off-the-shelf platforms (allogeneic CARs, \u03b3\u03b4-CAR, CAR-NK, RNA CARs), and early human experience with CD19- and BCMA-directed T cell engagers in rheumatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Collectively, these findings position cellular therapies as powerful, potentially transformative options for highly selected patients with severe, refractory lupus and autoimmune rheumatic disease, but also underscore the need for disciplined trial design, long-term safety surveillance, and strategies to ensure equitable access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001159","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:00:12Z","timestamp":1773907212000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Cellular therapies for rheumatic disease"],"prefix":"10.1097","volume":"38","author":[{"given":"Fotios","family":"Koumpouras","sequence":"first","affiliation":[{"name":"Section of Rheumatology Allergy and Immunology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caricchio","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"R1-20260401","first-page":"385","article-title":"Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2","volume":"156","author":"Eberlein","year":"1982","journal-title":"J Exp Med"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N Engl J Med"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of CAR-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus","volume":"383","author":"Morand","year":"2023","journal-title":"BMJ"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"R12-20260401","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"R15-20260401","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","article-title":"Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective","volume":"90","author":"Hoover","year":"2016","journal-title":"Kidney Int"},{"key":"R16-20260401","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/ndt\/gfl208","article-title":"Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?","volume":"21","author":"Grootscholten","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R17-20260401","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R18-20260401","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2020-217200","article-title":"Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework","volume":"79","author":"Zhao","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R19-20260401","doi-asserted-by":"crossref","first-page":"e2320851","DOI":"10.1001\/jamanetworkopen.2023.20851","article-title":"Comparative effectiveness of adalimumab vs. tofacitinib in patients with rheumatoid arthritis in Australia","volume":"6","author":"Deakin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R20-20260401","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R21-20260401","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R22-20260401","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R23-20260401","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"REGENCY Trial Investigators. Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"R24-20260401","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"R25-20260401","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"R26-20260401","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"R27-20260401","first-page":"e142","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies","volume":"62","author":"Taubmann","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R28-20260401","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"R29-20260401","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R30-20260401","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2023-180547","article-title":"CD19-targeted CAR-T cells in refractory systemic autoimmune diseases: a monocentric experience from the first fifteen patients","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"key":"R31-20260401","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R32-20260401","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R33-20260401","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R34-20260401","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"MG-001 Study Team. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, nonrandomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"R35-20260401","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R36-20260401","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/BOR.0000000000001012","article-title":"Chimeric antigen receptors: \u201cCARs\u201d in the fast lane for rheumatology","volume":"36","author":"Johnson","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"R37-20260401","doi-asserted-by":"crossref","first-page":"1630569","DOI":"10.3389\/fimmu.2025.1630569","article-title":"CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"R38-20260401","doi-asserted-by":"crossref","first-page":"e45698","DOI":"10.1097\/MD.0000000000045698","article-title":"Advances and prospects of CAR-T cell therapy in autoimmune disease treatment","volume":"104","author":"Li","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"R39-20260401","first-page":"101968","article-title":"Advancing autoimmune rheumatic disease treatment: CAR-T cell strategies and clinical trial advances","volume":"38","author":"Smith","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R40-20260401","first-page":"5846","article-title":"CAR-T cell therapy for rheumatoid arthritis: current status and perspectives","volume":"71","author":"Zhang","year":"2025","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"R41-20260401","doi-asserted-by":"crossref","first-page":"e70139","DOI":"10.1002\/acr2.70139","article-title":"Lupus Clinical Investigators Network. A guide for initiating and managing chimeric antigen receptor T cell therapy clinical trials in autoimmune rheumatic diseases","volume":"7","author":"Caricchio","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"R42-20260401","doi-asserted-by":"crossref","first-page":"1625166","DOI":"10.3389\/fimmu.2025.1625166","article-title":"CAR-T therapy: pioneering a new era in the treatment of autoimmune disease","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"R43-20260401","first-page":"109015","article-title":"Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune disease","volume":"275","author":"Liu","year":"2025","journal-title":"Clin Immunol"},{"key":"R44-20260401","doi-asserted-by":"crossref","first-page":"e70112","DOI":"10.1002\/acr2.70112","article-title":"Associations between pre-existing autoimmunity and chimeric antigen receptor T cell therapy toxicity for cancer treatment","volume":"7","author":"Challener","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"R45-20260401","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2665-9913(25)00100-6","article-title":"A new toxicity syndrome in patients with autoimmune disease treated with CAR T-cell therapy","volume":"7","author":"Good","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R46-20260401","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S2665-9913(24)00240-6","article-title":"Barriers to CAR T-cell therapy in rheumatology","volume":"7","author":"Lungova","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R47-20260401","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R48-20260401","first-page":"567","article-title":"Immune reset after CD19 CAR-T therapy in systemic sclerosis and inflammatory myopathy: longitudinal immunophenotyping","volume":"77","author":"Wang","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"(Suppl 9)","key":"R49-20260401","article-title":"Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease \u2013 data from the CASTLE Phase I\/II basket study [abstract]","volume":"77","author":"Hagen","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R50-20260401","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"R51-20260401","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R53-20260401","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"key":"R54-20260401","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"issue":"(Suppl 9)","key":"R55-20260401","first-page":"1130","article-title":"Safety of bispecific T-cell engager therapy in autoimmune disease [abstract]","volume":"76","author":"Hagen","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R56-20260401","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"R57-20260401","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/art.42677","article-title":"Effects of B cell depletion by CD19-targeted chimeric antigen receptor T cells in a murine model of systemic sclerosis","volume":"76","author":"Avouac","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R58-20260401","doi-asserted-by":"crossref","first-page":"e001742","DOI":"10.1136\/lupus-2025-001742","article-title":"Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis","volume":"12","author":"Gerber","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"(suppl 9)","key":"R59-20260401","article-title":"ADI-001: an allogeneic CD20-targeted \u03b3\u03b4 CAR T cell therapy with potential for improved tissue homing in autoimmune indications [abstract]","volume":"76","author":"Moreno","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:01:15Z","timestamp":1775030475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001159","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}